Grothey, A., Sargent, D., Goldberg, R. M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22 (2004), 1209–14.CrossRefGoogle ScholarPubMed

Grothey, A. and Sargent, D. Overall survival of patients with advanced colorectal cancer (CRC) correlates with availability of 5-fluorouracil, irinotecan and oxaliplatin regardless of whether doublet or single agent therapy is used first-line. Program and Proceedings of the 2006 Gastrointestinal Cancers Symposium (San Francisco, California, 2006), abstract, 282.

Tournigand, C., Andre, T., Achille, E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22 (2004), 229–37.CrossRefGoogle ScholarPubMed

Cunningham, D., Humblet, Y., Siena, S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351 (2004), 337–45.CrossRefGoogle ScholarPubMed

Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350 (2004), 2335–42.CrossRefGoogle ScholarPubMed

Andre, T., Boni, C., Mounedji-Boudiaf, L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350 (2004), 2343–51.CrossRefGoogle ScholarPubMed

Wolmark, N., Wieand, H. S., Kuebler, J. P., et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol, 23 (2005), abstr LBA3500.CrossRefGoogle Scholar

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol, 10 (1992), 896–903.CrossRef

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol, 12 (1994), 960–9.CrossRef

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol, 16 (1998), 301–8.CrossRef

Kohne, C. H., Wils, J., Lorenz, M., et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization for Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol, 21 (2003), 3721–8.CrossRefGoogle ScholarPubMed

Piedbois, P. and Buyse, M.What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project. Ann Oncol, 4:suppl. 2 (1993), 15–19.CrossRefGoogle ScholarPubMed

Gramont, A., Figer, A., Seymour, M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18 (2000), 2938–47.CrossRefGoogle ScholarPubMed

Douillard, J. Y., Cunningham, D., Roth, A. D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355 (2000), 1041–7.CrossRefGoogle ScholarPubMed

Kohne, C. H., Cutsem, E., Wils, J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol, 23 (2005), 4856–65.CrossRefGoogle ScholarPubMed

Goldberg, R. M., Sargent, D. J., Morton, R. F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22 (2004), 23–30.CrossRefGoogle ScholarPubMed

Cunningham, D., Pyrhonen, S., James, R. D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (1998), 1413–18.CrossRefGoogle ScholarPubMed

Saltz, L. B., Cox, J. V., Blanke, C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343 (2000), 905–14.CrossRefGoogle ScholarPubMed

Cutsem, E., Twelves, C., Cassidy, J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 19 (2001), 4097–106.CrossRefGoogle ScholarPubMed

Giantonio, B. J., Catalano, P. J., Meropol, N. J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol, 23:suppl. 1 (2005), abstr 2.CrossRefGoogle Scholar

Hochster, H. S., Welles, L., Hart, L., et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. J Clin Oncol, 23:suppl. 249 (2005), abstr 3515.CrossRefGoogle Scholar

Yarden, Y. and Sliwkowski, M. X.Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2 (2001), 127–37.CrossRefGoogle ScholarPubMed

Spano, J. P., Lagorce, C., Atlan, D., et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol, 16 (2005), 102–8.CrossRefGoogle ScholarPubMed

Rubio, Díaz E., Tabernero, J., Cutsem, E., et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol, 23 (2005), abstr 3535.Google Scholar

Chung, K. Y., Shia, J., Kemeny, N. E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23 (2005), 1803–10.CrossRefGoogle Scholar

Gordon, M. S., Cunningham,, D.Managing patients treated with bevacizumab combination therapy. Oncology, 69:suppl. 3 (2005), 25–33.CrossRefGoogle ScholarPubMed

Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol, 91 (2005), 173–80.CrossRefGoogle ScholarPubMed

Schrag, D., Chung, K. Y., Flombaum, C., et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst, 97 (2005), 1221–4.CrossRefGoogle ScholarPubMed

Moertel, C. G., Fleming, T. R., Macdonald, J. S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med, 322 (1990), 352–8.CrossRefGoogle ScholarPubMed

Wolmark, N., Rockette, H., Fisher, B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol, 11 (1993), 1879–87.CrossRefGoogle ScholarPubMed

NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. Jama, 264 (1990), 1444–50.CrossRef

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol, 17 (1999), 1356–63.CrossRef

Figueredo, A., Charette, M. L., Maroun, J., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol, 22 (2004), 3395–407.CrossRefGoogle ScholarPubMed

Mamounas, E., Wieand, S., Wolmark, N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol, 17 (1999), 1349–55.CrossRefGoogle Scholar

Gray, R. G., Barnwell, J., Hills, R., et al. QUASAR: a randomised study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol, 23:246 (2004), abstr 3501.Google Scholar

Benson, A. B., 3rd, Schrag, D., Somerfield, M. R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22 (2004), 3408–19.CrossRefGoogle Scholar

Ychou, M., Raoul, J. L., Douillard, J. Y., et al. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol, 23:suppl. 246 (2005), abstr 3502.CrossRefGoogle Scholar

Cutsem, E., Labianca, R., Hossfeld, D., et al. Randomized phase III trial conparing infused irintecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/DA (F) in stage III colon cancer patients (pts). J Clin Oncol, 23:suppl. 3 (2005), abstr LBA8.Google Scholar

Kapiteijn, E., Marijnen, C. A., Nagtegaal, I. D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345 (2001), 638–46.CrossRefGoogle ScholarPubMed

Marijnen, C. A., Peeters, K., Putter, H., et al. Long term results, toxicity and quality of life in the TME trial. Program and Proceedings of the 2005 Gastrointestinal Cancers Sympossium, Hollywood, Florida (2005), abstr 166.

Swedish Rectal Cancer Trial: improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med, 336 (1997), 980–7.CrossRef

Roh, M. S., Colangelo, L., Wieand, S., et al. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. Proc Am Soc Clin Oncol, 22:suppl. 246 (2004), abstr 3505.Google Scholar

Sauer, R., Becker, H., Hohenberger, W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351 (2004), 1731–40.CrossRefGoogle ScholarPubMed

Gerard, J., Bonnetain, F., Conroy, T., et al. Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3-4 rectal cancers : results of the FFCD 9203 randomized trial. Proc Am Soc Clin Oncol, 23:suppl. 247 (2005), abstr 3504.Google Scholar

Bosset, J. F., Calais, G., Mineur, L., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results – EORTC 22921. J Clin Oncol, 23 (2005), 5620–7.CrossRefGoogle ScholarPubMed

Chau, I., Brown, G., Cunningham, D., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol, 24 (2006), 668–74.CrossRefGoogle ScholarPubMed

Adam, R., Avisar, E., Ariche, A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol, 8 (2001), 347–53.Google ScholarPubMed

Alberts, S. R., Horvath, W. L., Sternfeld, W. C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol, 23 (2005), 9243–9.CrossRefGoogle ScholarPubMed

Bismuth, H., Adam, R., Levi, F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg, 224 (1996), 509–20, discussion 520–2.CrossRefGoogle ScholarPubMed

Giacchetti, S., Itzhaki, M., Gruia, G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 10 (1999), 663–9.CrossRefGoogle ScholarPubMed

Pozzo, C., Basso, M., Cassano, A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol, 15 (2004), 933–9.CrossRefGoogle ScholarPubMed

Nordlinger, B., Sorbye, H., Debois, M., et al. Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. J Clin Oncol, 23 (2005), abstr 3528.CrossRefGoogle Scholar